$1.36
-0.11 (-7.48%)
Open$1.43
Previous Close$1.47
Day High$1.57
Day Low$1.31
52W High$3.44
52W Low$1.21
Volume—
Avg Volume16.4K
Market Cap58.39M
P/E Ratio—
EPS$-0.02
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,135.3% upside
Current
$1.36
$1.36
Target
$44.00
$44.00
$29.80
$44.00 avg
$55.04
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.74M | 5.58M | 6.05M |
| Net Income | 1.11M | 1.28M | 1.11M |
| Profit Margin | 19.3% | 22.9% | 18.3% |
| EBITDA | 2.54M | 2.28M | 2.52M |
| Free Cash Flow | 874.9K | 1.03M | 1.03M |
| Rev Growth | +19.1% | +13.5% | +5.7% |
| Debt/Equity | 1.60 | 1.67 | 1.62 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |